Is InspireMD, Inc. (NASDAQ:NSPR) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating InspireMD, Inc. at current levels.
CGuard Prime is the first real challenger to Boston Scientific's carotid stent monopoly, and NSPR trades like it doesn't exist.
Where NSPR is headed
The US carotid stent market has been a duopoly frozen in time. Boston Scientific and Cordis have owned it for the better part of two decades with technology that predates the iPhone. Into that stagnant pond, InspireMD dropped CGuard Prime, a mesh-covered stent that clinical data suggests actually prevents the strokes these procedures are supposed to prevent. FDA approval came in mid-2025. The commercial ramp started slow, as every medical device launch does, because hospital committees move at hospital-committee speed. That ramp is what the current $39M market cap is telling you the market has given up on.
Read the full Compass Direction on NSPR
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $0.48).
See the full NSPR analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is InspireMD, Inc. (NASDAQ:NSPR) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating InspireMD, Inc. at current levels. CGuard Prime is the first real challenger to Boston Scientific's carotid stent monopoly, and NSPR trades like it doesn't exist.
What is NSPR's Compass Score?
InspireMD, Inc. scores 40/100 on Alexandria's Compass, placing it in the "Neutral" tier. Scores blend eight factors and update weekly.
What is the price target for NSPR?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the NSPR page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.